Jonatan Barrera-Chimal

Studying the mechanisms of cardiovascular complications in chronic kidney disease.

[Jonatan Barrera-Chimal @barrera_chimal]

@YuukiObata1026 @NIDDKgov Awesome! Congrats!!

[United Nations @UN]

Simple steps can help protect your kidneys:

⚖️ Maintain a healthy body weight
🥗 Eat a nutritious diet
🏃🏽‍♀️ Be active
💧 Drink water
🚭 Don't smoke
❤️ Control your blood pressure
💊 Don't self-medicate

Thursday is #WorldKidneyDay: https://t.co/fWVDbH0nCk

via @pahowho

[CasGerarduzzi @CasGerarduzzi]

What tumors “eat” shapes immunity 🍎➡️🛡️
Our new editorial describes how methylmalonic acid drives macrophage polarization in ccRCC and remodels the microenvironment 🌐
Biomarkers + therapy opportunities ahead 🎯💊https://t.co/LsL4vAgEox

[CasGerarduzzi @CasGerarduzzi]

New in Molecular Biomedicine! 🧪🧬We identify SMOC2 as protective in AKI: via ITGB3, it suppresses ERK–CCND1–CDK4/6, enforces G1 arrest ⛔️➡️🧫, limits DNA damage 🧯 and apoptosis, and reduces AKI→CKD progression.CDK4/6 inhibition phenocopies this 💊🛑Read more ⬇️ @Mol_Biomed

[Journal of Molecular Endocrinology @JMolEndo]

New Review: Jonatan Barrera-Chimal, Anand Vaidya & Frederic Jaisser explore the potential clinical advantages of a novel treatment, aldosterone synthase inhibitors (ASi), for cardiovascular–kidney–metabolic syndrome.

Subscribers can read the full article: https://t.co/lkeSh0etIa

[Jonatan Barrera-Chimal @barrera_chimal]

@KSusztak @NatureGenet @KonstantinKltz Amazing work! Congratulations @KSusztak !

[NEJM @NEJM]

Presented at #ERA25:

In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: https://t.co/4Gf0LboOCp

@ERAkidney

[Jonatan Barrera-Chimal @barrera_chimal]

The power of science 🤯!!

[NEJM @NEJM]

Brief Report: Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease https://t.co/B695kT9DRn

Editorial: Progress in the Development of N-of-1 Therapy https://t.co/PzvWMNfyVP

Science behind the Study: Personalized Gene Editing to Treat an Inborn Error of Metabolism https://t.co/mJSKHr5HIR

#ASGCT2025 | @ASGCTherapy

[World Kidney Day @worldkidneyday]

Kidney disease often develops silently, with no early symptoms. If you are at risk, regular checks are key for early detection and management.

#WorldKidneyDay 2025 focuses on detecting kidney disease early.

#AreYourKidneysOK ❓ Take the quiz: https://t.co/06fgpGXBE3

@ISNkidneycare

#WorldKidneyDay #AreYourKidneysOK #KidneyHealthMatters

[World Kidney Day @worldkidneyday]

Your kidneys are incredible organs that work tirelessly for you! About the size of a fist, they are located deep in your abdomen, just below the rib cage.

Explore more about kidney health topics 👉 https://t.co/Yl3YTHvsQZ

#WorldKidneyDay #AreYourKidneysOK #KidneyHealthMatters

[NDT @NDTsocial]

Upcoming drug targets for kidney protective effects in chronic kidney disease

🆓https://t.co/jwah5Fbr6k

[NDT @NDTsocial]

Mineralocorticoid receptor antagonism for non-diabetic kidney disease

🔓https://t.co/6i3oU4QNDc

[Rafeeque @rafeequemavoor]

Free scientific illustrations for biologists! 😍

@NIH has released a library of 500+ free scientific illustrations to create figures, presentations, and illustrations!

all freely available in the public domain.

Retweet and spread the message!
https://t.co/p1bD1kxO7H

[NEJM @NEJM]

Presented at #KidneyWk:

Two years of empagliflozin slowed kidney disease progression or cardiovascular death. In a post-trial study, empagliflozin had additional cardiorenal benefits after discontinuation. Full post-trial study results: https://t.co/yVvVg7V37b

[CasGerarduzzi @CasGerarduzzi]

🚨 PhD Opportunity 🚨
Passionate about #renaldiseases (#CKD #AKI), acute #inflammation, cellular #senescence, & #fibrosis? Join our team to uncover the molecular pathways driving kidney injury & discover therapeutic 🎯s

🧬 Details in 🧵👇

[Rafael Kramann, MD PhD @rkramann]

1/16) We are excited to share our recent paper “ADAMTS12 promotes fibrosis by restructuring extracellular matrix to enable activation of injury-responsive fibroblasts” published today @Jclinicalinvest led by @KonradHoeft and @Lars_K0ch https://t.co/3JkwsN8eZ7

[Muthu Vaduganathan @mvaduganathan]

🔥 A new therapeutic era in #HFpEF

#FINEARTSHF with definitive evidence supporting the role of the non-steroidal MRA finerenone at #ESCCongress

Now in @NEJM

https://t.co/iRGr1fQ2jM

[Katalin Susztak @KSusztak]

Semaglutide with 24% reduction in on Kidney outcomes in Patients with Type 2 Diabetes | ⁦@NEJM⁩ the FLOW trial https://t.co/fcvdkXet75

[Nature Reviews Nephrology @NatRevNeph]

We are extremely pleased to publish this Consensus Statement from @ISNkidneycare, @ERAkidney and @ASNKidney, and supported by regional societies, advocating for the recognition of kidney disease as a major #NCD driver of premature mortality. @WHO

https://t.co/YcQpZFFZ2i

[World Kidney Day @worldkidneyday]

Your kidneys are amazing organs and work really hard for you! Each roughly the size of your fist, kidneys are located deep in the abdomen, beneath the rib cage. Learn more about your amazing kidneys : https://t.co/Yl3YTHvsQZ

#WorldKidneyDay #KidneyHealthForAll